RedPath Integrated Pathology, Inc. Awarded Medicare Reimbursement Coverage for PathFinderTG(R)

PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc. (“RedPath”) announced today that its genomic-based cancer diagnostic test, PathFinderTG®, has been approved by Highmark Medicare Services for reimbursement coverage.
MORE ON THIS TOPIC